Debrisoquin sulfate | CAS#581-88-4 | guanidine derivative

MedKoo Cat#: 317584 | Name: Debrisoquin sulfate

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Debrisoquine is a derivative of guanidine. It is an antihypertensive drug similar to guanethidine. Debrisoquine is frequently used for phenotyping the CYP2D6 enzyme, a drug metabolizing enzyme.

Chemical Structure

Debrisoquin sulfate

CAS#581-88-4 (sulfate)

Theoretical Analysis

MedKoo Cat#: 317584

Name: Debrisoquin sulfate

CAS#: 581-88-4 (sulfate)

Chemical Formula: C20H28N6O4S

Exact Mass: 0.0000

Molecular Weight: 448.54

Elemental Analysis: C, 53.56; H, 6.29; N, 18.74; O, 14.27; S, 7.15

Price and Availability

Size	Price	Availability
50mg	USD 350.00	2 Weeks
100mg	USD 650.00	2 Weeks
250mg	USD 1,150.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

581-88-4 (sulfate) 1131-64-2 (free base) 1131-65-3 (HBr) 1131-66-4 (HCl)

Synonym

Debrisoquine; Debrisoquin; Debrisochinum; Isocaramidine; Tendor; Debrisoquina; Debrisoquin sulfate; Isocaramidine sulfate; Ro 5-3307/1; Ro5-3307/1

IUPAC/Chemical Name

3,4-dihydro-1H-isoquinoline-2-carboximidamide; sulfate (2:1)

InChi Key

CAYGYVYWRIHZCQ-UHFFFAOYSA-N

InChi Code

InChI=1S/2C10H13N3.H2O4S/c2*11-10(12)13-6-5-8-3-1-2-4-9(8)7-13;1-5(2,3)4/h2*1-4H,5-7H2,(H3,11,12);(H2,1,2,3,4)

SMILES Code

N=C(N1CC2=C(C=CC=C2)CC1)N.N=C(N3CC4=C(C=CC=C4)CC3)N.O=S(O)(O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 448.54 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Maas JW, Contreras SA, Seleshi E, Bowden CL. Dopamine metabolism and disposition in schizophrenic patients. Studies using debrisoquin. Arch Gen Psychiatry. 1988 Jun;45(6):553-9. doi: 10.1001/archpsyc.1988.01800300049005. PMID: 3377641. 2: Sternberg DE, Heninger GR, Roth RH. Plasma homovanillic acid as an index of brain dopamine metabolism: enhancement with debrisoquin. Life Sci. 1983 May 23;32(21):2447-52. doi: 10.1016/0024-3205(83)90370-3. PMID: 6855448. 3: Riddle MA, Shaywitz BA, Leckman JF, Anderson GM, Shaywitz SE, Hardin MT, Ort SI, Cohen DJ. Brief debrisoquin administration to assess central dopaminergic function in children. Life Sci. 1986 Mar 17;38(11):1041-8. doi: 10.1016/0024-3205(86)90239-0. PMID: 3456480. 4: Ward SA, Walle T, Walle UK, Wilkinson GR, Branch RA. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther. 1989 Jan;45(1):72-9. doi: 10.1038/clpt.1989.11. PMID: 2910639. 5: Parker RB, McCollam PL, Bauman JL. Propafenone: a novel type Ic antiarrhythmic agent. DICP. 1989 Mar;23(3):196-202. doi: 10.1177/106002808902300301. PMID: 2655298. 6: Bayes M, Rabasseda X, Prous JR. Gateways to Clinical Trials. Methods Find Exp Clin Pharmacol. 2002 Apr;24(3):159-84. PMID: 12087878. 7: Schultz FB. Clinical study of the antihypertensive effects of debrisoquin sulfate in combination with hydrochlorothiazide. J Med Assoc State Ala. 1966 Aug;36(2):147-53. PMID: 5329755. 8: Blechman M, Sokol C, Moser M. Debrisoquin sulfate: a clinical evaluation of a new antihypertensive agent. Curr Ther Res Clin Exp. 1969 Feb;11(2):71-6. PMID: 4975816. 9: Idle JR, Mahgoub A, Angelo MM, Dring LG, Lancaster R, Smith RL. The metabolism of [14C]-debrisoquine in man. Br J Clin Pharmacol. 1979 Mar;7(3):257-66. doi: 10.1111/j.1365-2125.1979.tb00930.x. PMID: 371651; PMCID: PMC1429493. 10: Riddle MA, Jatlow PI, Anderson GM, Cho SC, Hardin MT, Cohen DJ, Leckman JF. Plasma debrisoquin levels in the assessment of reduction of plasma homovanillic acid. The debrisoquin method. Neuropsychopharmacology. 1989 Jun;2(2):123-9. doi: 10.1016/0893-133x(89)90015-8. PMID: 2742727. 11: Pierce DM. A review of the clinical pharmacokinetics and metabolism of the alpha 1-adrenoceptor antagonist indoramin. Xenobiotica. 1990 Dec;20(12):1357-67. doi: 10.3109/00498259009046634. PMID: 1981634. 12: LURIA MH, FREIS ED. TREATMENT OF HYPERTENSION WITH DEBRISOQUIN SULFATE (DECLINAX). Curr Ther Res Clin Exp. 1965 May;7:289-96. PMID: 14286208. 13: Steventon GB, Heafield MT, Sturman S, Waring RH, Williams AC. Xenobiotic metabolism in Alzheimer's disease. Neurology. 1990 Jul;40(7):1095-8. doi: 10.1212/wnl.40.7.1095. PMID: 2356011. 14: Biron P. Un nouvel antihypertenseur sympathoplégique: le sulfate de débrisoquine [New sympathoplegic antihypersensive agent: debrisoquin sulfate]. Union Med Can. 1973 May;102(5):1134-5. French. PMID: 4712043. 15: Bozkurt A, Basci NE, Isimer A, Sayal A, Kayaalp SO. Polymorphic debrisoquin metabolism in a Turkish population. Clin Pharmacol Ther. 1994 Apr;55(4):399-401. doi: 10.1038/clpt.1994.48. PMID: 8162666. 16: Onesti G, LaSchiazza D, Brest AN, Moyer JH. Cardiac and renal hemodynamic effects of debrisoquin sulfate in hypertensive patients. Clin Pharmacol Ther. 1966 Jan-Feb;7(1):17-20. doi: 10.1002/cpt19667117. PMID: 5325582. 17: ABRAMS WB, POCELINKO R, KLAUSNER M, HANAUER L, WHITMAN EN. CLINICAL PHARMACOLOGICAL STUDIES WITH DEBRISOQUIN SULFATE, A NEW ANTIHYPERTENSIVE AGENT. J New Drugs. 1964 Sep-Oct;4(5):268-83. doi: 10.1002/j.1552-4604.1964.tb00372.x. PMID: 14218621. 18: Brøsen K, Gram LF. Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine. Eur J Clin Pharmacol. 1989;37(2):155-60. doi: 10.1007/BF00558224. PMID: 2792169. 19: O'Brien BW. The management of essential hypertension. JAMA. 1974 Aug 5;229(6):693-4. PMID: 4408383. 20: Boudet C, Peyrin L, Tavitian E, Claustre J, Favre R. Studies on the central or peripheral origin of free and sulfated 3,4-dihydroxyphenylacetic acid in rat plasma. Eur J Pharmacol. 1984 Aug 17;103(3-4):295-301. doi: 10.1016/0014-2999(84)90490-4. PMID: 6149138.